Alpha 2.0

» Articles » PMID: 34944721

Epigenome-Wide Histone Acetylation Changes in Peripheral Blood Mononuclear Cells in Patients with Type 2 Diabetes and Atherosclerotic Disease

Overview

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Dec 24

PMID 34944721

Citations 4

Authors

Authors

Pradeep Bompada

Isabel Goncalves

Chuanyan Wu

Rui Gao

Jiangming Sun

Bilal Ahmad Mir

Cheng Luan

Erik Renstrom

Leif Groop

Jianping Weng

Ola Hansson

Andreas Edsfeldt

Yang De Marinis

Affiliations

Affiliations

Soon will be listed here.

Abstract

There is emerging evidence of an association between epigenetic modifications, glycemic control and atherosclerosis risk. In this study, we mapped genome-wide epigenetic changes in patients with type 2 diabetes (T2D) and advanced atherosclerotic disease. We performed chromatin immunoprecipitation sequencing (ChIP-seq) using a histone 3 lysine 9 acetylation (H3K9ac) mark in peripheral blood mononuclear cells from patients with atherosclerosis with T2D ( = 8) or without T2D (ND, = 10). We mapped epigenome changes and identified 23,394 and 13,133 peaks in ND and T2D individuals, respectively. Out of all the peaks, 753 domains near the transcription start site (TSS) were unique to T2D. We found that T2D in atherosclerosis leads to an H3K9ac increase in 118, and loss in 63 genomic regions. Furthermore, we discovered an association between the genomic locations of significant H3K9ac changes with genetic variants identified in previous T2D GWAS. The transcription factor 7-like 2 () rs7903146, together with several human leukocyte antigen () variants, were among the domains with the most dramatic changes of H3K9ac enrichments. Pathway analysis revealed multiple activated pathways involved in immunity, including type 1 diabetes. Our results present novel evidence on the interaction between genetics and epigenetics, as well as epigenetic changes related to immunity in patients with T2D and advanced atherosclerotic disease.

Citing Articles

Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.

Karakasis P, Theofilis P, Patoulias D, Vlachakis P, Antoniadis A, Fragakis N Int J Mol Sci. 2025; 26(5).

PMID: 40076813 PMC: 11900163. DOI: 10.3390/ijms26052196.

Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.

Khan A, Jandeleit-Dahm K Nat Rev Cardiol. 2025; .

PMID: 39805949 DOI: 10.1038/s41569-024-01115-w.

Phase Ib study of the oral PI3Kδ inhibitor linperlisib in patients with advanced solid tumors.

Li J, Xue J, Liu T, Feng Y, Xu N, Huang J Int J Clin Oncol. 2024; 30(2):241-251.

PMID: 39538003 PMC: 11785675. DOI: 10.1007/s10147-024-02657-2.

Transcriptomic analysis of Paraoxonase 1 expression in hepatocellular carcinoma and its potential impact on tumor immunity.

Dong L, Dong C, Yu Y, Jiao X, Zhang X, Zhang X Clin Transl Oncol. 2024; 27(2):612-629.

PMID: 39031295 DOI: 10.1007/s12094-024-03598-y.

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade.

Tsai Y, Schlom J, Donahue R J Exp Clin Cancer Res. 2024; 43(1):82.

PMID: 38493133 PMC: 10944611. DOI: 10.1186/s13046-024-02969-1.

References

1.

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

2.

Van Rooij E, Olson E . MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest. 2007; 117(9):2369-76. PMC: 1952642. DOI: 10.1172/JCI33099. View

3.

Scott R, Scott L, Magi R, Marullo L, Gaulton K, Kaakinen M . An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. Diabetes. 2017; 66(11):2888-2902. PMC: 5652602. DOI: 10.2337/db16-1253. View

4.

Kim J, Kim J, Song K, Lee Y, Seo J, Jelinek J . Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta. 2006; 1772(1):72-80. DOI: 10.1016/j.bbadis.2006.10.004. View

5.

El-Osta A, Brasacchio D, Yao D, Pocai A, Jones P, Roeder R . Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008; 205(10):2409-17. PMC: 2556800. DOI: 10.1084/jem.20081188. View

6.

Malek V, Sharma N, Gaikwad A . Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy. Curr Mol Pharmacol. 2018; 12(1):61-71. DOI: 10.2174/1874467212666181122092300. View

7.

Frostegard J . Immune mechanisms in atherosclerosis, especially in diabetes type 2. Front Endocrinol (Lausanne). 2013; 4:162. PMC: 3810619. DOI: 10.3389/fendo.2013.00162. View

8.

Greissel A, Culmes M, Burgkart R, Zimmermann A, Eckstein H, Zernecke A . Histone acetylation and methylation significantly change with severity of atherosclerosis in human carotid plaques. Cardiovasc Pathol. 2016; 25(2):79-86. DOI: 10.1016/j.carpath.2015.11.001. View

9.

Grant S . The Locus: A Genetic Window Into the Pathogenesis of Type 1 and Type 2 Diabetes. Diabetes Care. 2019; 42(9):1624-1629. PMC: 6702598. DOI: 10.2337/dci19-0001. View

10.

Noble J, Valdes A . Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep. 2011; 11(6):533-42. PMC: 3233362. DOI: 10.1007/s11892-011-0223-x. View

11.

De Marinis Y, Cai M, Bompada P, Atac D, Kotova O, Johansson M . Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney. Kidney Int. 2016; 89(2):342-53. DOI: 10.1016/j.kint.2015.12.018. View

12.

Davey C, Sargent D, Luger K, Maeder A, Richmond T . Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol. 2002; 319(5):1097-113. DOI: 10.1016/S0022-2836(02)00386-8. View

13.

Kremlitzka M, Nowacka A, Mohlin F, Bompada P, De Marinis Y, Blom A . Interaction of Serum-Derived and Internalized C3 With DNA in Human B Cells-A Potential Involvement in Regulation of Gene Transcription. Front Immunol. 2019; 10:493. PMC: 6433827. DOI: 10.3389/fimmu.2019.00493. View

14.

Khyzha N, Alizada A, Wilson M, Fish J . Epigenetics of Atherosclerosis: Emerging Mechanisms and Methods. Trends Mol Med. 2017; 23(4):332-347. DOI: 10.1016/j.molmed.2017.02.004. View

15.

Manolio T, Collins F, Cox N, Goldstein D, Hindorff L, Hunter D . Finding the missing heritability of complex diseases. Nature. 2009; 461(7265):747-53. PMC: 2831613. DOI: 10.1038/nature08494. View

16.

Altshuler D, Hirschhorn J, Klannemark M, Lindgren C, Vohl M, Nemesh J . The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000; 26(1):76-80. DOI: 10.1038/79216. View

17.

Bompada P, Atac D, Luan C, Andersson R, Omella J, Ottosson Laakso E . Histone acetylation of glucose-induced thioredoxin-interacting protein gene expression in pancreatic islets. Int J Biochem Cell Biol. 2016; 81(Pt A):82-91. DOI: 10.1016/j.biocel.2016.10.022. View

18.

Zhu S, Goldschmidt-Clermont P, Dong C . Inactivation of monocarboxylate transporter MCT3 by DNA methylation in atherosclerosis. Circulation. 2005; 112(9):1353-61. DOI: 10.1161/CIRCULATIONAHA.104.519025. View

19.

Li Y, Zhu J, Tian G, Li N, Li Q, Ye M . The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol. 2010; 8(11):e1000533. PMC: 2976721. DOI: 10.1371/journal.pbio.1000533. View

20.

Kannel W, McGee D . Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979; 2(2):120-6. DOI: 10.2337/diacare.2.2.120. View